Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Man Group plc trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 15.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,968 shares of the biotechnology company’s stock after selling 4,168 shares during the quarter. Man Group plc owned about 0.08% of Arcturus Therapeutics worth $373,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Empire Life Investments Inc. increased its holdings in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after buying an additional 128,771 shares during the last quarter. Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after buying an additional 3,705 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Arcturus Therapeutics by 6.8% in the 4th quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company’s stock worth $28,587,000 after buying an additional 107,635 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Arcturus Therapeutics by 52.7% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 13,461 shares of the biotechnology company’s stock worth $241,000 after buying an additional 4,647 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ARCT shares. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Citigroup reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research note on Tuesday, May 13th. Wall Street Zen raised shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Finally, BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $57.80.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $12.20 on Tuesday. The stock has a market cap of $330.88 million, a price-to-earnings ratio of -5.50 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a 1 year low of $8.04 and a 1 year high of $45.00. The firm has a 50-day moving average of $11.35 and a two-hundred day moving average of $14.92.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $1.06. The company had revenue of $29.38 million during the quarter, compared to analysts’ expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.